Skip to main content

Psyence Biomedical Ltd.

PBM
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001985062

No open-market purchases or sales by Psyence Biomedical Ltd. insiders were filed in the last 90 days; 9 institutions reported holding it in 13F filings for Q2 2026, worth $1.24M in total; no superinvestor holds it.

Other share classesPBMWW

Q4 2024 vs. Q3 2024

How the institutions holding Psyence Biomedical Ltd. changed between Q3 2024 and Q4 2024.

All holders in Q4 2024All holders in Q3 2024

13F holders of PBM: Q3 2024 compared with Q4 2024
MeasureQ3 2024Q4 2024Change
Holders1211−1
Shares2.01M749.9K−1.26M (−62.8%)
Value$200.8K$1.53M+$1.33M (+662.9%)

New holders (6)

Institutions that held Psyence Biomedical Ltd. at the end of Q4 2024 but not at the end of Q3 2024.

Institutions new to PBM in Q4 2024
InstitutionSharesValue% of portfolio
Hudson Bay Capital Management LP380,000$743.7K0.00%
Harraden Circle Investments, LLC182,323$384.7K0.31%
Essential Planning, LLC.73,278$162.6K0.00%
Virtu Financial LLC12,692$27.0K0.00%
Scientech Research LLC11,183$23.6K0.01%
Connective Capital Management, LLC11,149$23.5K0.03%

Sold out (7)

Institutions that held Psyence Biomedical Ltd. at the end of Q3 2024 and filed for Q4 2024 without it.

Institutions that sold out of PBM in Q4 2024
InstitutionShares, Q3 2024Value, Q3 2024
Cantor Fitzgerald, L. P.337,000$33.7K
Stonehage Fleming Financial Services Holdings Ltd80,500$8.05K
Morgan Stanley48,407$4.84K
Jane Street Group, LLC45,963$4.60K
Two Sigma Securities, LLC14,989$1.50K
Geode Capital Management, LLC10,488$1.05K
JPMorgan Chase & Co2$0